Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 17, 2017

Primary Completion Date

October 6, 2022

Study Completion Date

October 6, 2022

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

Immediate Release (IR) Formulation

Immediate Release (IR) Formulation

DRUG

Gastro-Retentive (GR) Formulation

Gastro-Retentive (GR) Formulation

DRUG

Dexamethasone

Dexamethasone

DRUG

Pomalidomide

Pomalidomide

Trial Locations (20)

3168

Research Site, Clayton

6000

Research Site, Perth

6150

Research Site, Murdoch

10021

Research Site, New York

20817

Research Site, Bethesda

28204

Research Site, Charlotte

30322

Research Site, Atlanta

31008

Research Site, Pamplona

33612

Research Site, Tampa

37007

Research Site, Salamanca

44195

Research Site, Cleveland

44718

Research Site, Canton

53226

Research Site, Milwaukee

63110

Research Site, St Louis

78229

Research Site, San Antonio

90069

Research Site, West Hollywood

60637-6613

Research Site, Chicago

07601

Research Site, Hackensack

T2N 2T9

Research Site, Calgary

M5G 2C1

Research Site, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY